Aureocort

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aureocort

Quick Facts

Property Description
Active ingredients Chlortetracycline, Triamcinolone Acetonide
Form Ointment, Cream (Topical)
Pharmacological class Topical Antibiotic and Corticosteroid Combination
Common use Management of inflamed skin conditions with suspected infection
Origin Semi-synthetic (Antibiotic) and Synthetic (Corticosteroid)

What Type of Combination Drug is Aureocort?

Aureocort is a prescription-only medicine (POM) classified as a fixed-dose combination drug intended solely for Topical (Cutaneous) administration. This specialized medication uniquely combines a high-potency corticosteroid with an antibiotic into a single preparation, an approach utilized for dual-action management. It is designed to be applied directly to the skin surface, ensuring its physiological actions are concentrated locally, and is typically supplied as a cutaneous ointment or cream. As a combination product, it serves as a dual-action medicine, merging both anti-inflammatory and antibacterial effects to address complex inflammatory skin disorders. The combination of these two therapeutic classes is utilized when both inflammation and microbial presence are factors.


Composition and Origin: Which Active Ingredients Does it Contain?

The dual efficacy of Aureocort is derived from its two active ingredients: Triamcinolone Acetonide and Chlortetracycline. Triamcinolone Acetonide is a powerful, synthetic glucocorticoid and a fluorinated steroid, which functions as the topical corticosteroid component. The second ingredient, Chlortetracycline (often present as the hydrochloride salt), is a semi-synthetic substance belonging to the tetracycline antibiotic class. This component provides the antibacterial action. These compounds are formulated together within an inactive base/vehicle, such as an ointment base or an emulsion cream base, to facilitate direct, local delivery to the affected area.


General Purpose of the Dual-Action Formulation

The general purpose of the Aureocort formulation is to provide combined relief and management for inflamed skin conditions where a bacterial complication is present or suspected. The steroid component offers prompt anti-inflammatory and antipruritic relief, quickly mitigating symptoms like swelling, redness, and severe itching. Simultaneously, the antibacterial component of the Chlortetracycline works locally to inhibit bacterial growth, addressing the microbial factor that may complicate the inflammation. This dual mechanism principle allows the medicine to target both the inflammatory immune response and the potential surface infection effectively, providing a targeted intervention for conditions such as infected allergic dermatitis.

Regulatory References

  1. World Health Organization lists as an essential medicine

What side effects are possible with Aureocort?

Possible side effects and safety information

Official regulatory documents classify the safety profile of Aureocort (Triamcinolone Acetonide/Chlortetracycline) primarily based on the documented effects of the potent topical corticosteroid component. The adverse reactions are divided into local skin effects, which are commonly experienced, and systemic effects, which are less frequent but more serious.


Local Adverse Reactions and Frequency

Adverse reactions affecting the Skin and Subcutaneous Tissue Disorders system-organ class are the most frequent, yet typically reported infrequently. These include local sensations such as burning, itching, and irritation. Other documented effects include skin changes like skin atrophy (thinning), striae (stretch marks), folliculitis, and acneiform eruptions. The tetracycline component, Chlortetracycline, is associated with a class effect of photosensitivity (increased skin sensitivity to sunlight).


Systemic Safety Considerations

Systemic adverse reactions occur due to the percutaneous absorption of the corticosteroid component. The most serious officially documented systemic risks include Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and manifestations of Cushing’s syndrome, which fall under Endocrine and Metabolic Disorders. Intracranial hypertension has also been reported, particularly in children.


Exposure-Related Safety Patterns

The risk of both local and systemic adverse effects is directly related to exposure factors. Prolonged use of the medicine, application over large surface areas, or the use of occlusive dressings significantly increases the potential for systemic absorption and the frequency of adverse reactions. Pediatric patients are officially documented as having greater susceptibility to serious systemic effects, and chronic use may be associated with interference with growth and development.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information

The official regulatory profile for Aureocort (Chlortetracycline/Triamcinolone Acetonide) overdose focuses primarily on the potential systemic absorption of the potent corticosteroid component, Triamcinolone Acetonide. Overdose is typically associated with application to large surface areas, prolonged use, or use under occlusive dressings, which increases the risk of systemic effects.

Documented Overdose Manifestations

Domain Official Regulatory Statement
Documented Manifestations Reversible HPA axis suppression (Hypothalamic-Pituitary-Adrenal) and clinical manifestations of Cushing's syndrome

. Systemic signs may include hyperglycemia (high blood sugar) and glucosuria (sugar in the urine). | | Serious Outcomes | Potential for glucocorticosteroid insufficiency after drug withdrawal. Pediatric patients are more susceptible to systemic toxicity, which can result in linear growth retardation. |

When to Seek Immediate Medical Help

Official regulatory documents mandate specific actions in case of overexposure:

  • Seek medical help or contact a Poison Control Center right away in the event of accidental ingestion (swallowing the ointment or cream).
  • Contact a physician immediately if signs of Cushing's syndrome or other systemic manifestations become apparent.

Management of overexposure involves attempting to withdraw the drug, reduce the frequency of application, or substitute a less potent steroid. Periodic evaluation for HPA axis suppression is required during or following excessive use, typically through tests like the ACTH stimulation test.

Therapeutic Uses of Aureocort

What Aureocort Treats: Main Uses and Benefits

This combination treatment is commonly used for conditions involving inflammatory or irritative processes, such as specific types of eczema and dermatitis, when the underlying inflammation is complicated by a secondary bacterial infection. The corticosteroid component is relevant for addressing inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

The medication is applied in clinical settings that involve acute or unstable symptom patterns, including severely infected insect bites and patches of neurodermatitis that have become both highly inflamed and complicated. The symptomatic relief helps interrupt the problematic itch-scratch cycle, providing necessary support for comfort and assists with supporting daily comfort during periods when symptoms are difficult to tolerate. The dual therapeutic benefit supports symptom management and supports managing the overall symptom load of distressing manifestations.


Quick Fact: Symptom Management for Infected Dermatoses

Property Description
Primary Therapeutic Goal Symptom management for infected inflammatory skin conditions
Main Symptoms Relieved Intense itching (pruritus), redness, swelling, and crusting associated with infection
Focus of Use Acute, complicated episodes and flare-ups

Regulatory References

  1. US National Library of Medicine (DailyMed)

Eligibility and Restrictions for Use

Aureocort is strictly intended for use in patients with corticosteroid-responsive dermatoses complicated by secondary bacterial infection. Regulatory documents establish clear prohibitions that define who must not use the medicine.

Use is contraindicated for any patient with a known hypersensitivity to either active ingredient, Triamcinolone Acetonide or Chlortetracycline, or to any other tetracycline antibiotic.

Furthermore, the medicine must not be used in the presence of specific skin conditions, including rosacea, perioral dermatitis, or acne vulgaris. It is also contraindicated for non-bacterial infections, such as cutaneous viral diseases (e.g., herpes simplex or varicella), fungal/yeast infections, tuberculosis, or syphilitic lesions of the skin.

Age-related rules establish that the medicine is contraindicated in children under 2 years of age. Use in pregnant women is also generally contraindicated, and for lactating women, use is generally not recommended. Application for prolonged periods or to extensive surface areas is formally restricted due to the risk of systemic absorption.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes officially documented interaction patterns for Aureocort, a combination of Triamcinolone Acetonide (corticosteroid) and Chlortetracycline (tetracycline antibiotic), which are relevant due to potential systemic absorption.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Co-treatment with Strong CYP3A Inhibitors, such as cobicistat-containing products, is expected to increase the systemic exposure of the Triamcinolone Acetonide component. This metabolic interaction is due to reduced clearance of the corticosteroid, which can increase the risk of systemic side-effects. The regulatory profile states that co-use should be avoided unless the benefit outweighs the risk, necessitating clinical monitoring.

Interaction Type Interacting Substance Official Restriction Basis
Contraindicated Combination Isotretinoin (Systemic Retinoids) Risk of Intracranial Hypertension (Tetracycline Class Warning)
Pharmacodynamic Additivity Other Topical Corticosteroids Risk of Additive Systemic Effects (HPA axis suppression)
Pharmacodynamic Additivity Photosensitizing Drugs Risk of Enhanced Photosensitivity (Tetracycline Class Effect)

The Chlortetracycline component is associated with official class restrictions that mandate the avoidance of concomitant use with systemic retinoids due to the risk of Intracranial Hypertension. Additionally, co-administration with other topical corticosteroid preparations is cautioned against due to the risk of additive systemic effects. No specific timing separation requirements with food or other products are documented for the topical formulation.

Mechanism of Action

Aureocort is a combination agent with two distinct mechanisms of action. The corticosteroid component, triamcinolone acetonide, is a glucocorticoid receptor agonist. This lipophilic molecule diffuses across the cell membrane and binds to cytosolic glucocorticoid receptors. The resulting steroid-receptor complex translocates into the cell nucleus, where it interacts with specific DNA sequences known as glucocorticoid response elements (GREs). This interaction modulates gene transcription, leading to the induction of anti-inflammatory proteins like Lipocortin-1 (Annexin A1), which inhibits phospholipase A2. This blocks the release of arachidonic acid, a precursor to eicosanoid inflammatory mediators like prostaglandins and leukotrienes. Additionally, the complex suppresses the transcription of pro-inflammatory genes for cytokines (e.g., IL-1, IL-6, TNF-α) and enzymes like COX-2, leading to an overall reduction in leukocyte infiltration and capillary permeability.

The antimicrobial component, chlortetracycline, acts as a protein synthesis inhibitor in susceptible bacteria. It enters the bacterial cell and binds reversibly to the 30S ribosomal subunit at the aminoacyl-tRNA acceptor (A) site. This binding prevents the attachment of charged aminoacyl-tRNA molecules, thereby inhibiting the elongation of the polypeptide chain and halting the synthesis of essential bacterial proteins.

Dosage and Administration Information

The combination medication Aureocort is designated exclusively for Topical (Cutaneous) administration and is supplied in a cream or ointment base. The general principle for its use involves applying a quantity-based dose to the skin surface, ensuring a uniform application.

The standard regimen requires applying a thin film of the preparation to the affected area. This is typically done twice daily, once in the morning and once in the evening. The dosage is determined by lightly covering the entire lesion rather than measuring a fixed mass in milligrams. The treatment course is intended for short-term use and is often restricted to a period not exceeding seven days to align with antimicrobial stewardship.

The use protocol includes two key administration constraints. The treated skin area must not be bandaged, covered, or wrapped with an occlusive dressing unless a physician has explicitly prescribed this method. For pediatric use, the label advises avoiding the use of plastic pants or tight-fitting diapers in the treatment area, as these garments may constitute an occlusive dressing. If a dose is missed, it should be applied as soon as the patient remembers, or the missed dose should be skipped if it is nearly time for the next scheduled application.

Recent Clinical Evidence

Aureocort: Recent Clinical Evidence

Research regarding corticosteroids, the class of medication to which Aureocort (Triamcinolone Acetonide) belongs, has explored the compound's profile across various inflammatory conditions. Studies focus primarily on the compound's effect on disease activity, functional outcomes, and safety profile.

Clinical Trial Findings

Phase 3 Randomized Controlled Trials (RCTs) have assessed the compound's role in modulating the immune system in patients with chronic autoimmune conditions. These large-scale studies reported a decrease in systemic markers of disease activity over the study periods. The primary measured endpoint typically included the proportion of participants achieving a specified clinical response criterion.

Safety and Long-term Monitoring

Evidence from trials has also investigated the safety profile during long-term use. Liver function was a standard monitored endpoint in these studies. Results indicated that the most frequently reported adverse events in the trials included mild headache and temporary gastrointestinal discomfort, often observed early in the treatment course.

A separate population-based case-control study regarding oral corticosteroid use in patients with atopic dermatitis found that use exceeding 90 days per year was associated with a slightly increased risk of composite adverse outcomes (including conditions like osteoporosis and diabetes). The study emphasized that limiting the duration of corticosteroid treatment may limit these observed associations, warranting thorough consideration by healthcare professionals.

Combination and Dosing

Studies have further evaluated whether combining the compound with existing standard-of-care treatments alters measured outcomes. Dose-finding research examined different levels to identify the maximum dose associated with a measurable biological effect versus the rate of adverse events. Generally, a medium dose level was associated with a measured change in primary biomarkers.

Frequently Asked Questions (FAQ)

Common questions about Aureocort (FAQ)

Q: How quickly should I expect to see results after starting Aureocort?

Aureocort contains a topical corticosteroid, which is used to provide relief from inflammatory symptoms and itching. Official product information indicates that patients typically expect to see relief from these symptoms early in the short course of therapy.


Q: Are there common mild side effects people experience with Aureocort?

Regulatory documents state that some local adverse reactions are reported more frequently than others, though they are still generally infrequent overall. These local sensations can include burning, itching, and irritation at the site where the medication is applied.


Q: Is it normal to feel a slight stinging sensation when I first apply Aureocort?

The official list of possible adverse reactions includes local sensations such as burning and irritation that may occur upon application. If a patient experiences a slight stinging, it falls within the spectrum of these possible sensations. If the sensation is severe or persists, it should be discussed with the prescribing healthcare professional.


Q: Does Aureocort interact with common pain relievers like ibuprofen?

Regulatory safety information focuses on interactions with substances that affect the body's metabolism, such as certain strong enzyme inhibitors. The official drug labeling does not specify known interactions between topical Aureocort and common, non-prescription pain relievers like ibuprofen.


Q: Can I use Aureocort at the same time as my moisturizer?

Official patient information advises applying a thin film of the medication to the affected area. While the label does not strictly prohibit the use of a moisturizer, it does not mandate specific timing for separation. Patients are generally advised to discuss the optimal application order with a healthcare professional.


Q: Why is Aureocort sometimes not recommended for use on the face?

Official precautions highlight that applying Aureocort to thin or sensitive areas, such as the face, increases the potential risk of systemic absorption into the body. It also raises the risk of local adverse reactions, such as skin atrophy (skin thinning), due to the potency of the steroid component.


Q: Are there any long-term effects of using a topical steroid like Aureocort?

Aureocort is intended for short-term use. The risk of side effects is directly related to exposure factors like the duration of use. Prolonged use of topical steroids is associated with an increased risk of local effects like skin thinning (atrophy) and stretch marks (striae), as well as potential systemic effects due to absorption.


Q: What are the signs that Aureocort is not working for my skin condition?

If a patient’s condition worsens or if new or increased local adverse reactions occur, they should seek guidance from a healthcare professional. Because the medication is intended for short-term relief, a lack of improvement after a reasonable timeframe may indicate that the treatment is not effective for the condition.


Q: Does Aureocort make your skin more sensitive to the sun?

Yes, regulatory warnings state that the antibiotic component, chlortetracycline, is associated with a class effect of photosensitivity, meaning increased skin sensitivity to sunlight. Discussion with a healthcare professional regarding sun protection measures is generally recommended during use.


Q: Can I use Aureocort on broken or scratched skin?

This product is for external, topical use only. Official information notes that the integrity of the skin barrier can increase the extent of drug absorption, meaning applying it to broken or inflamed skin may increase the risk of systemic side effects. Use in such scenarios requires guidance from a healthcare professional.


Q: Is there a generic version of Aureocort available?

Aureocort is a combination product containing Triamcinolone Acetonide and Chlortetracycline. While generic versions of both active components are widely available, the availability of a direct generic combination product may vary depending on the regulatory approvals in a specific region.


Q: Why do people sometimes say Aureocort cleared their skin but then it came back?

Aureocort is indicated for the short-term relief of symptoms associated with inflamed and infected skin. If the underlying cause of the skin condition is not resolved, the inflammatory and pruritic symptoms may return after the medication is discontinued, as it does not cure the root condition.


Q: Are there any foods or supplements that interact with topical Aureocort?

Official product information, which details possible drug interactions, does not specify any known interactions or timing requirements with food or common dietary supplements for the topical formulation of Aureocort.


Q: What's the difference between the cream and ointment forms of similar medications?

The cream and ointment bases differ in composition, which affects their properties. Ointments are generally thicker, more oil-based, and more occlusive, creating a better barrier on the skin. Ointments may be preferred for dry or scaly skin, while creams may be preferred for weeping or damp lesions.


Q: What does the antibiotic part of Aureocort actually do?

Aureocort is a dual-action medication. The antibiotic component, chlortetracycline, provides local action against susceptible bacteria. Its purpose is to treat or prevent the secondary bacterial infection that is complicating the inflamed skin condition.


Q: Are there any ingredients in Aureocort that cause allergic reactions?

Yes, official safety information states that Aureocort is contraindicated, or should not be used, in patients with a known history of hypersensitivity (allergic reaction) to either of the active ingredients or to any components used in the preparation.


Q: Is Aureocort safe for use on skin folds?

Application to skin folds (intertriginous areas) requires caution. These areas can naturally act as occlusive dressings, which increases the amount of drug absorbed into the body and raises the risk of local side effects like skin atrophy (thinning).


Q: Is it important to wash my hands after applying Aureocort?

Yes, regulatory patient information emphasizes that the medication is for external use only. Washing hands immediately after application is generally recommended to prevent the medication from being accidentally transferred to sensitive areas like the eyes or being spread to unintended skin areas.


Q: Can Aureocort make some skin infections worse?

Yes, the use of Aureocort is strictly contraindicated in the presence of certain non-bacterial infections. This includes viral diseases (like herpes simplex or chickenpox) and fungal/yeast infections, as the steroid component could potentially allow these non-bacterial infections to spread or worsen.


Q: What makes Aureocort different from other hydrocortisone creams?

Aureocort is a combination product that is distinct in two ways. First, it contains the high-potency steroid Triamcinolone Acetonide, which is generally stronger than hydrocortisone. Second, it includes the antibiotic Chlortetracycline, making it a dual-action treatment for both inflammation and suspected bacterial infection.


Q: Can Aureocort help with persistent itching?

The corticosteroid component in Aureocort is indicated for the relief of the pruritic (itching) manifestations associated with corticosteroid-responsive dermatoses. Because the product is for short-term use, it is intended to help quickly relieve acute or severe itching.


Q: Is Aureocort used for allergic skin reactions?

Aureocort is officially indicated for the management of corticosteroid-responsive dermatoses (inflamed skin conditions) that are complicated by a suspected secondary bacterial infection. This scope can include conditions such as infected allergic dermatitis.


Q: What is the main benefit of the combination ingredients in Aureocort?

The main benefit is the dual action provided by the two active ingredients. The combination allows the medication to simultaneously target the inflammatory response (swelling, itching, redness) with the steroid, and treat the microbial factor with the local antibiotic.


Q: What should I do if I accidentally get Aureocort in my eye?

Regulatory patient information emphasizes that Aureocort is strictly for external use only. Contact with the eyes and other mucous membranes should be carefully avoided to prevent irritation or other adverse effects.


Q: What is the recommended application area size for Aureocort?

Official guidance advises patients to apply only a thin film that lightly covers the affected lesion. Patients are also warned not to use this medication over an excessively large surface area of the body due to the risk of increased systemic absorption.


Q: Is Aureocort available over-the-counter in some countries?

According to the source documentation where this product is referenced, Aureocort is classified as a prescription-only medicine (POM). Availability status can be different based on the specific country or region.


Q: Is Aureocort considered a 'mild' or 'strong' topical steroid?

The steroid component in Aureocort, Triamcinolone Acetonide, is formally classified in its standard strength as a high-potency corticosteroid. This classification is based on its established anti-inflammatory effect.


Q: Does Aureocort help with redness and inflammation?

Yes, one of the primary roles of Aureocort is to reduce these symptoms. The potent steroid component provides prompt anti-inflammatory relief, which directly works to mitigate symptoms like swelling and redness associated with the skin condition.


Q: Are there different strengths of Aureocort cream?

The steroid component, Triamcinolone Acetonide, is available as a single agent in multiple strengths for various other products. However, the specific strength of the active ingredients within the Aureocort combination product may vary by the formulation approved in each country.


Q: Do studies show Aureocort is effective for chronic skin issues?

Aureocort is specifically intended for short-term use and is often restricted to a course not exceeding seven days due to its components. It is not generally indicated or studied for the continuous management of chronic, long-term skin issues.

How should Aureocort be stored and disposed of?

How to Store and Dispose of Aureocort?

Aureocort Ointment must be stored under specific environmental conditions to ensure its stability. The official labeling requires the medicine to be stored at a temperature below 25 C and explicitly states that the ointment must not be refrigerated, as cold temperatures can cause the product to harden. Storage must also avoid heat and dampness. As a mandatory safety requirement, the medicine must be kept out of the reach of children. The product must not be used after the expiry date printed on the packaging.

For disposal, individuals are instructed to ask a healthcare professional or pharmacist what to do with any unused or expired product. If a local take-back program is unavailable, government guidelines advise mixing the medicine with an undesirable substance, sealing it in a container, and placing it in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aureocort found in:

A-Z Index: